These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Protective Effects of Glucagon-like Peptide 1 on Endothelial Function in Hypertension. Liu L; Liu J; Huang Y J Cardiovasc Pharmacol; 2015 May; 65(5):399-405. PubMed ID: 25384196 [TBL] [Abstract][Full Text] [Related]
45. Endothelial dysfunction: a strategic target in the treatment of hypertension? Tang EH; Vanhoutte PM Pflugers Arch; 2010 May; 459(6):995-1004. PubMed ID: 20127126 [TBL] [Abstract][Full Text] [Related]
46. A rationale for treatment of endothelial dysfunction in hypertension. Ruschitzka F; Corti R; Noll G; Lüscher TF J Hypertens Suppl; 1999 Feb; 17(1):S25-35. PubMed ID: 10340841 [TBL] [Abstract][Full Text] [Related]
48. Treatment with the arginase inhibitor N(omega)-hydroxy-nor-L-arginine improves vascular function and lowers blood pressure in adult spontaneously hypertensive rat. Bagnost T; Berthelot A; Bouhaddi M; Laurant P; André C; Guillaume Y; Demougeot C J Hypertens; 2008 Jun; 26(6):1110-8. PubMed ID: 18475148 [TBL] [Abstract][Full Text] [Related]
49. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Taddei S; Virdis A; Ghiadoni L; Magagna A; Salvetti A Circulation; 1998 Jun; 97(22):2222-9. PubMed ID: 9631871 [TBL] [Abstract][Full Text] [Related]
50. Endothelial dysfunction and hypertension in aging. Higashi Y; Kihara Y; Noma K Hypertens Res; 2012 Nov; 35(11):1039-47. PubMed ID: 22972557 [TBL] [Abstract][Full Text] [Related]
51. [Endothelial dysfunction and angiotensin-converting enzyme inhibitors in coronary disease]. Mélon P Rev Med Liege; 1998 Jun; 53(6):353-4. PubMed ID: 9713215 [TBL] [Abstract][Full Text] [Related]
52. Roles of oxidants, nitric oxide, and asymmetric dimethylarginine in endothelial function. Siekmeier R; Grammer T; März W J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):279-97. PubMed ID: 18945874 [TBL] [Abstract][Full Text] [Related]
53. [Hypertension and endothelial dysfunction]. Zoghi M; Nalbantgil I Anadolu Kardiyol Derg; 2002 Jun; 2(2):142-7, AXVIII. PubMed ID: 12134540 [TBL] [Abstract][Full Text] [Related]
54. Abnormal coronary vasomotion in hypertension: role of coronary artery disease. Frielingsdorf J; Kaufmann P; Seiler C; Vassalli G; Suter T; Hess OM J Am Coll Cardiol; 1996 Oct; 28(4):935-41. PubMed ID: 8837571 [TBL] [Abstract][Full Text] [Related]
55. Role of NO and angiotensin II in the early development of endothelial functions impairment and cardiac hypertrophy in deoxycorticosterone acetate-salt hypertension. K-Laflamme A; Oster L; Cardinal R; de Champlain J Can J Physiol Pharmacol; 1998 Jun; 76(6):665-75. PubMed ID: 9923405 [TBL] [Abstract][Full Text] [Related]
56. Combined oral contraceptive-induced hypertension is accompanied by endothelial dysfunction and upregulated intrarenal angiotensin II type 1 receptor gene expression. Olatunji LA; Seok YM; Igunnu A; Kang SH; Kim IK Naunyn Schmiedebergs Arch Pharmacol; 2016 Nov; 389(11):1147-1157. PubMed ID: 27447455 [TBL] [Abstract][Full Text] [Related]
57. Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension. Li Q; Youn JY; Cai H J Hypertens; 2015 Jun; 33(6):1128-36. PubMed ID: 25882860 [TBL] [Abstract][Full Text] [Related]
58. Endothelial Dysfunction and Hypertension. Konukoglu D; Uzun H Adv Exp Med Biol; 2017; 956():511-540. PubMed ID: 28035582 [TBL] [Abstract][Full Text] [Related]
59. Nitric oxide, angiotensin II, and reactive oxygen species in hypertension and atherogenesis. Schulman IH; Zhou MS; Raij L Curr Hypertens Rep; 2005 Feb; 7(1):61-7. PubMed ID: 15683588 [TBL] [Abstract][Full Text] [Related]